Proactive Investors - Run By Investors For Investors

OptiBiotix Health sweetener performs well in independent taste test

The company is developing sweet, natural, healthy fibres which are not digested in the human gut, and are therefore calorie-free
sugar cubes
The sweetener market is still dominated by sugar

An independent study has shown a sweetener developed by OptiBiotix Health PLC (LON:OPTI) scored well against competitors.

The Flavour and Sensory Science Centre at the University of Reading tested eight different samples.

It found the company's oligosaccharides were significantly sweeter than the other products tested, while being low in all “off-flavours” such as bitterness, sourness, staleness and saltiness.

The company is developing sweet, natural, healthy fibres under the SweetBiotix brand, which are not digested in the human gut, and are therefore calorie-free. 

Big potential market 

This would give the research firm entry to the US$100bn a year global sweetener market, which is still dominated by sugar.

OptiBiotix chief executive Stephen O'Hara said he was pleased with the results of the Reading study.

“This development creates the potential to replace existing unhealthy sugars with low calorie, healthy non-digestible fibres (SweetBiotix) with gut microbiome functionality.

“With growing concerns over the impact on health of traditional sugars and artificial sweeteners, the ability to develop sweet functional fibres puts OptiBiotix at the forefront of product development in this area of growing industry and commercial interest."

Human microbiome

The company’s specialism is the human microbiome, an ecosystem of bacteria and yeasts that reside in the gut and on the skin.

It is thought changes to the human flora can have an impact on health, hence the proliferation of functional foods such as yoghurts filled with probiotic, or good bacteria.

OptiBiotix’s focus is mainly on the gut with advances designed to tackle obesity, cholesterol and diabetes although the company does have a separately-quoted business developing skincare products.

In a note to clients, analysts at ‘house’ broker finnCap commented: “This positive taste study further demonstrates the potential for SweetBiotix to replace traditional sugars and artificial sweeteners as a bulk sugar replacement that contains no calories and improves microbiome diversity.”

In late afternoon trading, shares in Optibiotix were 1.6% higher at 635p.

--- Updates share price ---

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

cancer
May 14 2018
Physiomics' share price surged on a €500,000 contract for its virtual tumour software with Merck KgaA.
Widecells
September 27 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
CBD oil
November 15 2018
The company’s technology creates nano-scale emulsion mixtures that allow fluids to mix that normally don’t mix, such as CBD oil and water

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use